Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%

Exclusion Criteria

• •Prior treatments for prostate cancer, including radiotherapy, chemotherapy or endocrine therapy.
• •Non-acinar adenocarcinoma histology on biopsy.
• •Preoperative evidence of metastasis: nodal(N1), locally advanced(T3-4), or distant(M1) disease on imaging.
• •History of pelvic lymphadenectomy or radiotherapy.
• •Other malignancies within 5 years.
• •Contraindications to radical prostatectomy or being deemed surgically inoperable upon clinical assessment.
• •Contraindications to radiotherapy or intolerance determined by radiation oncologists.
• •Severe allergy to PSMA PET ligands or excipients.
• •Any other conditions precluding PSMA PET examination.